Skip to main content

Context Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

CNTX$0.20+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

September 30, 2024December 31, 2023
(Unaudited)(Note 3)
Assets
Current assets:
Cash and cash equivalents$84,801,556$14,449,827
Prepaid expenses and other current assets1,269,2651,597,384
Total current assets86,070,82116,047,211
Property and equipment, net14,89315,524
Operating lease right-of-use lease assets244,135—
Total assets$86,329,849$16,062,735
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$1,028,667$2,383,016
Accrued expenses and other current liabilities1,199,2051,808,699
Operating lease liabilities - current104,160—
Total current liabilities2,332,0324,191,715
Operating lease liabilities - non-current140,200—
Total liabilities2,472,2324,191,715
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding——
Common stock, $0.001 par value; 200,000,000 and 100,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 74,998,312 and 15,966,053 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively74,99815,966
Additional paid-in capital175,219,40579,909,644
Accumulated deficit(91,436,786)(68,054,590)
Total stockholders' equity83,857,61711,871,020
Total liabilities and stockholders' equity$86,329,849$16,062,735
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.